Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Interest & Investment Income (2021 - 2025)

Verrica Pharmaceuticals has reported Interest & Investment Income over the past 5 years, most recently at $205000.0 for Q4 2025.

  • Quarterly results put Interest & Investment Income at $205000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $929000.0 (down 34.44% YoY), and the annual figure for FY2025 was $929000.0, down 34.44%.
  • Interest & Investment Income for Q4 2025 was $205000.0 at Verrica Pharmaceuticals, up from $159000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for VRCA hit a ceiling of $822000.0 in Q3 2023 and a floor of $20000.0 in Q2 2022.
  • Median Interest & Investment Income over the past 5 years was $213000.0 (2024), compared with a mean of $284250.0.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 3030.0% in 2023 and later crashed 74.12% in 2024.
  • Verrica Pharmaceuticals' Interest & Investment Income stood at $27000.0 in 2021, then soared by 959.26% to $286000.0 in 2022, then surged by 176.92% to $792000.0 in 2023, then crashed by 74.12% to $205000.0 in 2024, then changed by 0.0% to $205000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $205000.0 (Q4 2025), $159000.0 (Q3 2025), and $228000.0 (Q2 2025) per Business Quant data.